The effectiveness of AstraZeneca vaccine is in question due to a test error

Registration of the coronavirus vaccine by the Anglo-Swedish company AstraZeneca is delayed because the test results are not true

As News Front previously reported, the Anglo-Swedish pharmaceutical company AstraZeneca, from which the USA had already pre-ordered the vaccine, had to stop the trial. Although AstraZeneca did not disclose the details of the incident, a source in The New York Times said that a participant in a UK trial had transverse myelitis, an inflammatory syndrome that affects the spinal cord.

The trials were later resumed and AstraZeneca announced that its vaccine’s efficacy is supposed to reach 90%. The information was received with jubilation in the USA, where 260,000 citizens were victims of coronavirus infection. However, the company made a mistake in the dosage for trial participants, which casts doubt on the research results.
Scientists and experts in the field have said that the mistakes made by the company undermine confidence in the results of the trials, The New York Times reports. Even Washington officials admitted that the situation is questionable. As a result, it is also less likely that regulators in the USA and European countries will allow the emergency use of AstraZeneca vaccine.

“I think they have really undermined the trust in their entire programme”, –  said Jeffrey Porges, an analyst at the investment bank SVB Leerink.